AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04697212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare team- + patient-directed intervention
Description: Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities, and will also complete a patient prompt list that elicits strategies that they prefer the healthcare team to use during their visit.
Study NCT04697212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare team-directed intervention
Description: Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities.
Study NCT04697212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthcare team-directed intervention
Description: Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities.
Study NCT05470075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18042 tablets
Description: Drug: HR 18042 tablets 175mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Study NCT05470075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18042 tablets
Description: Drug: HR 18042 tablets 225mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Study NCT05470075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18042 tablets
Description: Drug: HR 18042 tablets 275mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Study NCT05470075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride SR Tablets
Description: Drug: Tramadol hydrochloride SR Tablets 100mg and placebos match to HR18042 tablets Dosing frequency: single dose; Route of administration: oral
Study NCT05470075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Drug: Placebos match to HR18042 tablets and Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
Study NCT01230762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapoxetine
Description: 60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
Study NCT06646809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-ketoglutarate
Description: Alpha-ketoglutarate supplements
Study NCT06646809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT06646809 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care
Study NCT06646445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200mg IV q3w day 1 of 21-day cycle
Description: Pembrolizumab 200 mg via a 30-minute IV infusion q3w on Day 1 of each 21-day cycle; 8 cycles ± 9 additional cycles (17 cycles in total).
Study NCT06646445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Watch-and-wait approach
Description: Watch-and-wait strategy:~* TAP-CT scan every 3 months (± 7 days) for 2 years from inclusion.~* Colonoscopy with biopsies at months 3, 6, 12, 24.
Study NCT06646445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Standard of care surgery performed with a maximal delay of 21 days (3 weeks) from inclusion.
Study NCT06646445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Adjuvant chemotherapy (5-fluorouracil/capecitabine ± oxaliplatin 3 months to 6 months) will be prescribed according to the current guidelines, at the investigator's discretion.
Study NCT05492123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 40 mg in 4 ml Injection
Description: Nivolumab 1mg/kg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation
Study NCT05492123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab 200 MG in 40 ML Injection
Description: Ipilimumab 3mg/kg every 3 weeks for 4 cycles prior to radiation
Study NCT05492123 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg/m2/w or carboplatin AUC 2/w
Study NCT05492123 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg/m2/w or carboplatin AUC 2/w
Study NCT05436600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The exercise intervention group will undergo 12 weeks of AeroBal exercise training (approximately 3 times/week). Each exercise session will consist of a 5-minute warm-up walk, approximately 30 minutes of aerobic exercise at a goal of 60-75% HRmax, 15 minutes of balance exercises, and a 5-minute cool-down walk.
Study NCT05503875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
Description: Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
Study NCT04866680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized Circulating DNA follow-up
Description: FFPE tissue sample will be collected before and after surgery blood samples will be collected before and after surgery and every 3 to 4 months
Study NCT06314451 — intervention group
Intervention type: OTHER
Intervention: Cognitive Interview
Description: The study involves a single cognitive interview with a researcher, either online, by telephone, or face-to-face. People who want to take part will be given information about the study and asked to give written consent. Then they will be asked to talk about the wording of the questionnaire and how relevant it is to them.~Cognitive interviewing is recognized as a significant part of developing questionnaires for patient reported outcome measures (PROMs). The cognitive interviewing process used in PROM development will be adapted in this study to test the Steroid PRO in new disease populations. Cognitive interviewing will be carried out using pragmatic, light-touch interviews, underpinned by think aloud techniques and clean language principles.
Study NCT05414266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
Study NCT05414266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SADBE 5%
Description: SADBE 5% is a solution of 5% Squaric Acid Dibutyl Ester (SADBE) in acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
Study NCT04703361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo NaCl
Description: Placebo
Study NCT04703361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Niacin
Description: B3 vitamin, Niacin
Study NCT04703361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-3-OHB
Description: Na-3-OHB
Study NCT06412458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM83 CAR-T Cells
Description: IM83 CAR-T Cells, 5×10\^8 cells, 1×10\^9 cells, and 2×10\^9 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
Study NCT04853108 — intervention group
Intervention type: OTHER
Intervention: Remote Monitoring of COVID-19
Description: Remote monitoring of acute COVID-19 illness included use of a Medtronic pulse oximeter, photoplethysmography (PPG), patient-reported symptoms data, static vital signs captured during the course of the clinical evaluation and various physiomarkers.
Study NCT06517550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positive end-expiratory pressure while mechanical ventilation
Description: a parameter in ventilator
Study NCT04832750 — intervention group
Intervention type: DEVICE
Intervention: intermittent theta burst stimulation (iTBS) or sham stimulation
Description: 30 sessions of iTBS over 2 weeks (3 sessions per day, 5 days per week)
Study NCT05949541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg
Description: Everolimus is a kind of mTOR inhibitor which has been approved to use in several kinds of cancers, especially in metastatic breast cancer.
Study NCT05949541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK4/6 Inhibitor SHR6390
Description: Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
Study NCT05949541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDK4/6 Inhibitor SHR6390
Description: Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
Study NCT05949541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors
Description: Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
Study NCT05949541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors
Description: Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
Study NCT05057117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave thermolysis
Description: Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
Study NCT05057117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
Study NCT06545630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor antigen-sensitized DC vaccine
Description: subcutaneous administration
Study NCT04989972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSIL428
Description: 1 mg of psilocybin
Study NCT04989972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oyster mushroom
Description: 1 mg of oyster mushroom
Study NCT05639634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation
Description: Supplementation with Chlorella (1.5 g/d) in 3 capsules for 12 weeks.
Study NCT05639634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 week cardiovascular training programme
Description: Participants will be asked to complete a 12 week cycling training programme. This will consist of 4 X 50 min sessions per week. Each exercise session will include a warm-up phase (\~ 5 min), a main physical conditioning phase (\~ 40 min), and a cool-down phase (\~ 5 min).
Study NCT05639634 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 12 week cardiovascular training programme
Description: Participants will be asked to complete a 12 week cycling training programme. This will consist of 4 X 50 min sessions per week. Each exercise session will include a warm-up phase (\~ 5 min), a main physical conditioning phase (\~ 40 min), and a cool-down phase (\~ 5 min).
Study NCT05639634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplementation
Description: Supplementation with Placebo - microcrystalline cellulose (1.5 g/d) in 3 capsules for 12 weeks.
Study NCT05654779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-AMDR Cells Product
Description: Subjects will receive a conditioning regimen before treatment with LCAR-AMDR cells
Study NCT06496087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DEPREXIL
Description: The trial group will be administered 1 capsule of DEPREXIL orally every 8 hours for 6 months of treatment.
Study NCT04989972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSIL428
Description: 1 mg psilocybin
Study NCT04984759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).
Study NCT04984759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.
Study NCT06381154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06381154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06381154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT06381154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Undergo EUS
Study NCT06381154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT06381154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT06381154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT06381154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Description: Undergo lymph node biopsy
Study NCT06381154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI
Study NCT06381154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT06381154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05470361 — intervention group
Intervention type: PROCEDURE
Intervention: stellate ganglion block (SGB)
Description: The protocol for the SGB plus SCGB will be followed, wherein participants are given right-side procedures followed by left-side procedures on a different day if no initial improvement is seen. This procedure is carried out by injecting a local anesthetic into the neck to target the Stellate Ganglion and Superior Cervical Ganglion nerve bundles.
Study NCT06381154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo intratumoral photoradiation
Study NCT06381154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT and PET/MRI
Study NCT06381154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06381154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Given IV
Study NCT04946019 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Unity-based MR-Linac guided FSRT
Description: The FSRT was delivered using the Unity-based MR-Linac treatment machine, with a total dose of 30Gy in 5 fractions.
Study NCT05854615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells
Description: • Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
Study NCT05462288 — intervention group
Intervention type: DEVICE
Intervention: Entia Liberty
Description: Home monitoring blood analyser
Study NCT06140914 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics, miRNA studies and studies of blood cells from blood samples
Description: This is an observational study where we follow patients and save blood samples and biopsies for analysis as described above.
Study NCT05194228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecologial Momentary Assessment settings
Description: Various settings for ecological momentary assessments
Study NCT04903847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]
Description: Two-drug therapy
Study NCT04903847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
Description: Three-drug therapy
Study NCT05957445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active continuous Theta Burst Stimulation
Description: Each patient will receive a series of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, and subsequently a 600-pulse cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
Study NCT05957445 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham continuous Theta Burst Stimulation
Description: Each patient will receive a series of stimulation sequences，including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, and subsequently a 600-pulse sham cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
Study NCT05268822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Movement control exercise with or without specific breathing techniques
Study NCT06509945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: allogeneic peripheral blood stem cell transplantation
Description: Patients achieved response to treatment will receive allogeneic peripheral blood stem cell transplantation.
Study NCT05259306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insightec Exablate Neuro MR-guided focused ultrasound transducer
Description: This study will be utilizing the Insightec Exablate Neuro MR-guided focused ultrasound transducer to deliver low-intensity ultrasonic energy precisely and safely to the target region of the brain. MRgFUS has been FDA approved at high-intensity to treat essential tremor and Parkinson's disease associated tremor. Device premarket approval number (PMA) is P150038, and FDA approval notice was July 11, 2016. This study will be using this device not to make any lesions in the brain (as it is currently FDA approved), but instead to use the precision and non-invasive nature of the device to target the MD thalamus region of the brain at intensities currently approved by the FDA for transcranial ultrasound.
Study NCT04790851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAX+IIV4; COVAX+PPV23
Description: 1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
Study NCT04790851 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVAX only (1st and 2nd dose)
Description: 1st dose: COVAX only; 2nd dose: COVAX only
Study NCT04790851 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IIV4 for the 1st dose and PPV23 for the 2nd dose
Description: 1st dose: IIV4 only; 2nd dose: PPV23 only